Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2N | P61088 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19299535 | 0.90 | UBE2N (0.53) | UBE2NALDH1A1MAPTMEN1LMNA | |
| SCHEMBL19299545 | 0.90 | UBE2N (0.53) | UBE2NALDH1A1MAPTMEN1LMNA | |
| SCHEMBL19299380 | 0.88 | UBE2N (0.55) | UBE2NALDH1A1MAPTMEN1LMNA | |
| SCHEMBL19299546 | 0.84 | UBE2N (0.53) | UBE2NALDH1A1MAPTMEN1LMNA | |
| SCHEMBL19299534 | 0.84 | UBE2N (0.53) | UBE2NALDH1A1MAPTMEN1LMNA | |
| SCHEMBL19299540 | 0.84 | UBE2N (0.53) | UBE2NALDH1A1MAPTMEN1LMNA | |
| SCHEMBL19299385 | 0.77 | GAA (0.54) | ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL19299381 | 0.74 | UBE2N (0.54) | UBE2NALDH1A1MAPTMEN1LMNA | |
| SCHEMBL20403100 | 0.73 | KMT2A (0.51) | ALDH1A1MAPTFLT3MEN1KMT2A | |
| SCHEMBL19299383 | 0.72 | UBE2N (0.62) | UBE2NALDH1A1MAPTMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212183-B1 | SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS | UNIV ROCHESTER (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10028931-B2 | Synergistic compositions for treating microbial infections | UNIVERSITY OF ROCHESTER (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170246139-A1 | SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS | UNIVERSITY OF ROCHESTER (US) | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10028931-B2 | Synergistic compositions for treating microbial infections | RNASE1, RNASEL, RNASEH1 | UBE2N 2057/4885ALDH1A1 3822/4885MAPT 4406/4885 |
| US-20170246139-A1 | SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS | RNASE1, RNASEL, RNASEH1 | UBE2N 2057/4885ALDH1A1 3822/4885MAPT 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.